Skip to main content
CGTX
NASDAQ Life Sciences

Cognition Therapeutics Aligns with FDA on Pivotal Trial Design for Zervimesine in DLB Psychosis

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.66
Mkt Cap
$147.672M
52W Low
$0.25
52W High
$3.83
52W Position info
564% above low
Off High info
57% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

CGTX has more than doubled off its 52-week low of $0.25.

Summary

Cognition Therapeutics received official FDA feedback, confirming alignment on the design of a pivotal Phase 3 trial for zervimesine in DLB psychosis, setting a clear path for its lead drug candidate.


Key Events · Product Development and Regulatory · CGTX

  • FDA Alignment on Pivotal Trial

    The FDA has agreed that psychosis associated with Dementia with Lewy Bodies (DLB) could be an approvable outcome and aligned on key aspects of a pivotal trial design for zervimesine.

  • Pivotal Trial Design Details

    The Phase 3 study is expected to enroll DLB patients experiencing psychosis symptoms, including those on stable off-label antipsychotics, randomized to receive once-daily oral zervimesine or placebo for nine months.

  • Novel Primary Endpoint

    The company will collaborate with the FDA on the analytical and statistical details for using the Neuropsychiatric Inventory (NPI) as a novel primary endpoint for the pivotal trial.

  • Registrational Program Timeline

    The registrational program for zervimesine in DLB psychosis is expected to commence in mid-2027.


Analysis · CGTX · Life Sciences

This 8-K confirms the receipt of official written feedback from the FDA, detailing the alignment on key aspects of a pivotal Phase 3 trial for zervimesine in Dementia with Lewy Bodies (DLB) psychosis. This provides a clear regulatory path and trial design for their lead candidate, addressing a significant unmet medical need. The FDA's agreement on DLB psychosis as an approvable outcome and the use of a novel primary endpoint (NPI) are critical de-risking steps for the company.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CGTX was trading at $1.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $147.7M. The 52-week trading range was $0.25 to $3.83. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CGTX - Latest Insights

CGTX
Nov 05, 2026, 6:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.6833
Real-time Price: $0.6205 info
Change: -$0.0628 (-9%) info
Market Cap: $59.904M info
CGTX
Nov 05, 2026, 6:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6833
Real-time Price: $0.6205 info
Change: -$0.0628 (-9%) info
Market Cap: $59.904M info
CGTX
Oct 22, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.800
Real-time Price: $0.6205 info
Change: -$0.1795 (-22%) info
Market Cap: $59.904M info
CGTX
Oct 22, 2026, 6:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7995
Real-time Price: $0.6205 info
Change: -$0.179 (-22%) info
Market Cap: $59.904M info
CGTX
Oct 13, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.865
Real-time Price: $0.6205 info
Change: -$0.2445 (-28%) info
Market Cap: $59.904M info